Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ. Weiß, K. Dragnev, Tibor Csőszi et al.|Annals of Oncology|2019Cited by 173
Lung cancer chemoprevention: difficulties, promise and potential agents?K. Dragnev, Ronald A. Lubet, Yian Wang et al.|Expert Opinion on Investigational Drugs|2012Cited by 19